# Triumeq in Amyotrophic Lateral Sclerosis

> **NCT05193994** · PHASE3 · TERMINATED · sponsor: **Macquarie University, Australia** · enrollment: 419 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Dolutegravir, Abacavir and Lamivudine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05193994
- **Lead sponsor:** Macquarie University, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-24
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 419 (ACTUAL)
- **Why stopped:** A planned interim analysis resulted in the recommendation that the trial be stopped. The results showed no benefit of Triumeq for people with ALS compared with placebo on survival, the primary outcome measure.
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193994, "Triumeq in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05193994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*